Droxidopa
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314206

CAS#: 23651-95-8

Description: Droxidopa is a synthetic amino acid precursor which acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline) and it is used to increase the concentrations of these neurotransmitters in the body and brain. Unlike norepinephrine and epinephrine themselves, droxidopa is capable of crossing the protective blood–brain barrier (BBB). It is metabolized by aromatic L-amino acid decarboxylase (AAAD), also known as DOPA decarboxylase (DDC). Droxidopa works by increasing the levels of norepinephrine and epinephrine in the peripheral nervous system (PNS), which induces tachycardia or increased heart rate and hypertension or increased blood pressure, thus enabling the body to maintain blood flow upon and while standing. (Source: http://en.wikipedia.org/wiki/Droxidopa).


Chemical Structure

img
Droxidopa
CAS# 23651-95-8

Theoretical Analysis

MedKoo Cat#: 314206
Name: Droxidopa
CAS#: 23651-95-8
Chemical Formula: C9H11NO5
Exact Mass: 213.06372
Molecular Weight: 213.19
Elemental Analysis: C, 50.70; H, 5.20; N, 6.57; O, 37.52

Price and Availability

Size Price Availability Quantity
25.0mg USD 250.0 2 weeks
50.0mg USD 450.0 2 weeks
100.0mg USD 650.0 2 weeks
200.0mg USD 950.0 2 weeks
500.0mg USD 1750.0 2 weeks
1.0g USD 2650.0 2 weeks
2.0g USD 4950.0 2 weeks
Bulk inquiry

Synonym: SM5688; SM 5688; SM-5688; Droxidopa; trade name: Northera; LDOPS; L-threodihydroxyphenylserine

IUPAC/Chemical Name: (2R,3S)-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid

InChi Key: QXWYKJLNLSIPIN-SFYZADRCSA-N

InChi Code: InChI=1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m1/s1

SMILES Code: O=C(O)[C@H](N)[C@H](C1=CC=C(O)C(O)=C1)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 213.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Isaacson SH, Skettini J. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa. Vasc Health Risk Manag. 2014 Apr 3;10:169-76. doi: 10.2147/VHRM.S53983. eCollection 2014. PubMed PMID: 24729712; PubMed Central PMCID: PMC3979788.

2: Traynor K. Droxidopa approved for neurogenic orthostatic hypotension. Am J Health Syst Pharm. 2014 Apr 1;71(7):520. doi: 10.2146/news140024. PubMed PMID: 24644107.

3: Rodríguez S, Raurell I, Ezkurdia N, Augustin S, Esteban R, Genescà J, Martell M. The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats. Liver Int. 2014 Jan 19. doi: 10.1111/liv.12472. [Epub ahead of print] PubMed PMID: 24517276.

4: Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). J Parkinsons Dis. 2014;4(1):57-65. doi: 10.3233/JPD-130259. PubMed PMID: 24326693.

5: Hagiwara S. [Acute poisoning of droxidopa: report of a case]. Chudoku Kenkyu. 2013 Sep;26(3):244-5. Japanese. PubMed PMID: 24224390.

6: Wecht JM, Rosado-Rivera D, Weir JP, Ivan A, Yen C, Bauman WA. Hemodynamic effects of L-threo-3,4-dihydroxyphenylserine (Droxidopa) in hypotensive individuals with spinal cord injury. Arch Phys Med Rehabil. 2013 Oct;94(10):2006-12. doi: 10.1016/j.apmr.2013.03.028. Epub 2013 Apr 18. PubMed PMID: 23602882.

7: Coll M, Rodriguez S, Raurell I, Ezkurdia N, Brull A, Augustin S, Guardia J, Esteban R, Martell M, Genescà J. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats. Hepatology. 2012 Nov;56(5):1849-60. doi: 10.1002/hep.25845. Epub 2012 Oct 14. PubMed PMID: 22610782.

8: Saito S, Shioda K, Nishijima K. Dopamine dysregulation syndrome including mania related to coadministration of droxidopa. J Clin Psychopharmacol. 2012 Jun;32(3):428-9. doi: 10.1097/JCP.0b013e3182549243. PubMed PMID: 22561478.

9: Holmes C, Whittaker N, Heredia-Moya J, Goldstein DS. Contamination of the norepinephrine prodrug droxidopa by dihydroxyphenylacetaldehyde. Clin Chem. 2010 May;56(5):832-8. doi: 10.1373/clinchem.2009.139709. Epub 2010 Mar 5. PubMed PMID: 20207766.

10: Despas F, Pathak A, Berry M, Cagnac R, Massabuau P, Liozon E, Galinier M, Senard JM. DBH deficiency in an elderly patient: efficacy and safety of chronic droxidopa. Clin Auton Res. 2010 Jun;20(3):205-7. doi: 10.1007/s10286-009-0049-7. Epub 2010 Jan 9. PubMed PMID: 20063034.